{"url_path":"/sec/mdai/8-k/2026-07-08/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/1833498/0001213900-26-076349-index.html","accession_number":"0001213900-26-076349","cik":"0001833498","ticker":"MDAI","issuer_name":"Spectral AI, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1833498/0001213900-26-076349-index.html","primary_entity_key":"0001833498","primary_entity_name":"Spectral AI, Inc."},"word_count":413,"has_tables":true,"body_markdown":"**Item 5.02 Departure of Directors or Certain Officers; Election of\nDirectors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**\n\n** **\n\n(c) As announced in the press release attached\nto this Current Report on Form 8-K, the Board of Directors (the “Board”) of the Spectral AI, Inc. (the “Company”)\nhave appointed Darcy Bajko to the position of Chief Commercial Officer beginning on July 31, 2026 (the “Effective Date”).\n\n \n\nMrs. Bajko joins Spectral AI from MediView XR,\nwhere she spent the past five years in a series of commercial leadership roles, most recently serving as Vice President of Commercialization\nand Customer Success since 2024. At MediView, she helped shape the commercialization strategy for the company’s augmented reality visualization\nand navigation technologies, advancing image-guided procedures across interventional radiology, urology, oncology, and minimally invasive\nsurgery. During her tenure, Mrs. Bajko and team successfully launched three FDA-cleared augmented reality imaging platforms—MediScout™,\nOmnifyXR™, and XR90™—building the commercial organization from the ground up and driving revenue growth from pre-commercialization\nto more than $2.2 million. She also established strategic customer success programs and played a pivotal role in accelerating market adoption\nof the company’s innovative technology. Prior to joining MediView, Mrs. Bajko held commercial leadership positions of increasing responsibility\nwith Smith+Nephew, Integra LifeSciences, and OrthoHelix Surgical Designs, where she built extensive experience in orthopedic and medical\ndevice sales, commercialization, and market development. Mrs. Bajko holds a Bachelor of Journalism from Bowling Green State University\nand a Master of Business Administration from Fairleigh Dickinson University.\n\n \n\nMrs. Bajko, age 47, will receive annual base compensation\nof $315,000. She will be eligible for an annual target bonus of up to 30% of her annual base compensation, payable upon the achievement\nof certain milestones and performance goals, as specified by the Board. She will be granted stock options under and subject to the terms\nof the Company’s 2023 Long Term Incentive Plan on the date of employment, to acquire 150,000 shares of common stock of the Company\nat an exercise price as of the Effective Date. The stock options will vest annually with the first installment vesting on the first anniversary\nof the grant date and subsequent installments on each of the next two anniversary dates of the grant date thereafter, as may be applicable.\nUpon a change of control of the Company, the stock options will become fully vested prior to the change of control. A copy of Mrs. Bajko’s\nemployment agreement is furnished as Exhibit 99.1 to this Current Report on Form 8-K."}